Ann: Noxopharm IONIC Immuno-Oncology Trial Commences, page-12

too right.
not sure anyway why an ethics approval is considered price sensitive announcement. It’s not even Nox’s study.
it’s unlikely this pilot trial will be suitable for a regulatory agency so any talk that this will take over the world is premature.
the name dropping (of BMS) in these announcements and slides earlier this week is chutzpah. This trial isn’t a true collaboration between Nox & BMS. I do wonder what BMS head office would make of this announcement, wonder if they get to see before release because they might not be too chuffed about the way their drug Nivolumab is being written up. Could be read as hey Nivolumab bit of a dud in most cancers, here’s Nox the cavalry to make your drug work better.

let’s see trial progress and the data.